Abstract: A facility and a method for thermal cleaning and separation of metal parts is provided, desirably windings from a stator of an electric motor and/or generator, where the stator windings are embedded in an organic and insulating material, where the stator is placed and heated under controlled conditions in a heating chamber comprising a gas mixture of more than 86 vol % inert gas and less than 14 vol % oxygen, such that the organic covalent bonds of the organic material will undergo pyrolysis, resulting in the production of a char product and volatile organic products that will evaporate into the gas mixture in the heating chamber. The flue gas in the heating chamber including a mixture of oxygen, volatile organic products and inert gas is then subjected to an oxidation process by addition of a oxygen enriched gas mixture, resulting in the oxidation of the volatile organic products into CO2 and O2.

Abstract: The present invention relates to the combined use of nimorazole or a pharmaceutically acceptable salt thereof and chemo-radiotherapy. In particular, it relates to the combined use of nimorazole or a pharmaceutically acceptable salt thereof, chemotherapy and radiotherapy for patients suffering from laryngeal, hypopharyngeal and/or oropharyngeal squamous cell carcinoma (SCC).

Abstract: The present invention provides a method for determining the oxygen status of a cancer of an individual. The method comprise determining the transcriptional expression level of ADM (SEQ ID No:1), and/or at least one gene selected from ANKRD37 (SEQ ID NO.: 3), P4HA2 (SEQ ID NO.: 12), NDRG1 (SEQ ID NO: 10), SLC2A1 (SEQ ID NO:15), P4HA1 (SEQ ID NO.: 11), LOX (SEQ ID NO.: 9), C3orf28 (SEQ ID NO.: 6), BNIP3L (SEQ ID NO.: 5), BNIP3 (SEQ ID NO.:4), EGLN3 (SEQ ID NO.: 7), PDK1 (SEQ ID NO.: 13), PFKFB3 (SEQ ID NO.: 14), KCTD11 (SEQ ID NO.: 8), and/or ALDOA (SEQ ID NO.: 2), in a cancer sample. The transcriptional level is then correlated to the transcriptional level to at least one reference gene, and oxygen status 10 is then evaluated by comparing the correlated transcription level with a predetermined reference sample comprising cancer cells characterized by a high oxygen level.

Abstract: A method is provided for determining breast cancer, a predisposition to breast cancer, or the prognosis of a breast cancer in a subject, said method comprising in a sample from said subject determining the methylation status of at least one gene locus including regulatory sequences of said gene locus, wherein said genelocusis selected from the group consisting of PHOX2B, FLJ3247, GHSR, HOXB13, HTR1B, ONECUT, POU4F, WT1, LHX1, BC008699, BX161496, CA10, NR2E1, SIX6, SLC38A4, TITF, TMTM132D, CRH, NKX2-3 and HMX.

Abstract: The present invention provides a method for determining the oxygen status of a cancer of an individual. The method comprise determining the transcriptional expression level of ADM (SEQ ID No:1), and/or at least one gene selected from ANKRD37 (SEQ ID NO.: 3), P4HA2 (SEQ ID NO.: 12), NDRG1 (SEQ ID NO: 10), SLC2A1 (SEQ ID NO:15), P4HA1 (SEQ ID NO.: 11), LOX (SEQ ID NO.: 9), C3orf28 (SEQ ID NO.: 6), BNIP3L (SEQ ID NO.: 5), BNIP3 (SEQ ID NO.:4), EGLN3 (SEQ ID NO.: 7), PDK1 (SEQ ID NO.: 13), PFKFB3 (SEQ ID NO.: 14), KCTD11 (SEQ ID NO.: 8), and/or ALDOA (SEQ ID NO.: 2), in a cancer sample. The transcriptional level is then correlated to the transcriptional level to at least one reference gene, and oxygen status 10 is then evaluated by comparing the correlated transcription level with a predetermined reference sample comprising cancer cells characterized by a high oxygen level.

Abstract: The present invention relates to compositions, kits, and methods for providing a prognosis and/or determining a treatment course of action in a subject diagnosed with breast cancer. In particular, the present invention relates to gene expression signatures useful in the prognosis, diagnosis, and treatment of breast cancer.

Abstract: The present invention relates to treatment or prevention of radiation induced fibrosis using TNF-alpha antagonism. Preferably, TNF-alpha is antagonized by direct binding or by inhibition of synthesis. In a preferred embodiment, the invention comprises intraperitoneal administration of a chitosan-siRNA nanoparticle, wherein the siRNA is targeted to the mRNA encoding TNF-alpha.

Abstract: The invention relates to a method for the treatment of an EGFR-associated tumor comprising administration, to an individual in need thereof, of an anti-EGFR antibody in combination with radiotherapy and a radiosensitising agent. In one embodiment, the treatment further comprises administration of a chemotherapeutic agent.